Aytu Biopharma Inc expected to post a loss of 32 cents a share — Earnings Preview

Aytu Biopharma Inc is expected to show a fall in quarterly revenue when it reports results on September 22 for the period ending June 30 2026 The Denver Colorado-based company is expected to report a 18.9% decrease in revenue to $12.276 million from $15.14 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data. ​LSEG's mean analyst estimate for Aytu Biopharma Inc is for a loss of 32 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ​ Previous quarterly performance (using preferred earnings measure in US dollars). ​ QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI ENDING ARTESTIMAT ESTIMATE MET, SE % E® MISSED Mar. 31 2026 -0.46 -0.51 -0.53 Missed -3.9 Dec. 31 2026 -0.60 -0.60 -1.05 Missed -75 Sep. 30 2025 -0.23 -0.23 0.21 Beat 191.3​ Jun. 30 2025 -0.04 -0.04 -2.92 Missed -7,862.9 ​​Mar. -0.17 -0.17 0.21 Beat 223.5 31 2025 Dec. 31 2024 -0.28 -0.28 -0.26 Beat 7.1​ Sep. 30 2024 -0.34 -0.34 0.44 Beat 229.4 Jun. 30 2024 -0.45 -0.82 Missed -82.2 Thi